- Home
- KOD vs DAWN Comparison
KOD vs DAWN Comparison
Compare KOD & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KOD | DAWN |
|---|---|---|
| Founded | 2009 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | KOD | DAWN |
|---|---|---|
| Price | $25.28 | $11.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $28.29 | $27.56 |
| AVG Volume (30 Days) | 656.3K | ★ 1.8M |
| Earning Date | 01-01-0001 | 04-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 32.60 | ★ 56.96 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $131,161,000.00 |
| Revenue This Year | N/A | $18.59 |
| Revenue Next Year | N/A | $49.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.92 | $5.64 |
| 52 Week High | $31.18 | $13.20 |
Technical Indicators
Market Signals| Indicator | KOD | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 53.93 | 55.45 |
| Support Level | $21.51 | $11.37 |
| Resistance Level | $27.99 | $12.12 |
| Average True Range (ATR) | 2.02 | 0.69 |
| MACD | 0.33 | -0.02 |
| Stochastic Oscillator | 66.67 | 78.85 |
Price Performance
Historical ComparisonAbout KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.
About DAWN Day One Biopharmaceuticals Inc.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.